https://www.healthylivingmaldives.com/article/905467090-from-milestone-to-momentum-kraig-biocraft-leadership-travels-to-south-east-asia-following-record-setting-1-3-metric-ton-recombinant-spider-silk Healthy Living Maldives en PressRelease 2026-04-13T11:05:00+00:00 From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905466754-oxb-launches-fast-track-offering-for-aav-and-lentiviral-vector-platforms-accelerating-viral-vector-development-and-manufacture Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture https://ml-eu.globenewswire.com/media/3e905c0a-b28c-4981-ac57-745647779ad9/small/oxb-new-logo-png.png https://www.healthylivingmaldives.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://www.healthylivingmaldives.com/article/905466931-soleo-health-opens-new-ambulatory-infusion-center-in-louisville-kentucky Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 Soleo Health Opens New Ambulatory Infusion Center in Louisville, Kentucky https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.healthylivingmaldives.com/article/905466947-nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-company-s-first-chief-commercial-officer Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.healthylivingmaldives.com/article/905466972-kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.healthylivingmaldives.com/article/905466973-spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.healthylivingmaldives.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905467081-imagenebio-announces-30-million-private-placement Healthy Living Maldives en PressRelease 2026-04-13T11:00:00+00:00 ImageneBio Announces $30 Million Private Placement https://ml.globenewswire.com/media/ccccc30d-a51c-48d7-9aec-6b542240c611/small/imagene-logo-green-jpg.jpg https://www.healthylivingmaldives.com/article/905466794-ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules Healthy Living Maldives en PressRelease 2026-04-13T10:50:00+00:00 ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.healthylivingmaldives.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency Healthy Living Maldives en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://www.healthylivingmaldives.com/article/905463063-regeneron-and-telix-announce-strategic-radiopharma-collaboration Healthy Living Maldives en PressRelease 2026-04-13T10:30:00+00:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration Healthy Living Maldives en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.healthylivingmaldives.com/article/905459654-prosomnus-receives-fda-class-ii-clearance-for-rpmo2-osa-device Healthy Living Maldives en PressRelease 2026-04-13T10:00:00+00:00 ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device https://ml.globenewswire.com/media/333d9b0e-92b8-4e8b-ab32-6689f4113578/medium/prosomnus-rpmo2-osa-device-system.jpg https://www.healthylivingmaldives.com/article/905451931-smart-minimalism-supreme-efficiency-cuktech-15-charging-station-makes-its-debut-in-malaysia Healthy Living Maldives en PressRelease 2026-04-13T08:40:54+00:00 Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.healthylivingmaldives.com/article/905452017-berikut-adalah-terjemahan-siaran-akhbar-tersebut-ke-dalam-bahasa-melayu-minimalisme-pintar-kecekapan-ulung-stesen-pengecasan-cuktech-15-membuat Healthy Living Maldives en PressRelease 2026-04-13T08:40:54+00:00 Berikut adalah terjemahan siaran akhbar tersebut ke dalam Bahasa Melayu: Minimalisme Pintar, Kecekapan Ulung: Stesen Pengecasan CUKTECH 15 Membuat Kemunculan Sulung di Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.healthylivingmaldives.com/article/905445010-epitopea-strengthens-scientific-advisory-board-with-appointment-of-leading-authority-in-cancer-lisa-butterfield Healthy Living Maldives en PressRelease 2026-04-13T08:00:00+00:00 Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.healthylivingmaldives.com/article/905445013-epitopea-renforce-son-comit-consultatif-scientifique-avec-la-nomination-de-lisa-butterfield-figure-de-renom-dans-le-domaine-du-cancer Healthy Living Maldives en PressRelease 2026-04-13T08:00:00+00:00 Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.healthylivingmaldives.com/article/905445007-boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows Healthy Living Maldives en PressRelease 2026-04-13T07:51:00+00:00 Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.healthylivingmaldives.com/article/905445021-rising-uk-dental-costs-and-nhs-access-crisis-drive-record-demand-for-treatment-in-t-rkiye-dentspa-leads-the-response Healthy Living Maldives en PressRelease 2026-04-13T07:30:00+00:00 Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response https://ml-eu.globenewswire.com/media/53fb3ee2-7271-4c5f-b8b5-f4e6db89cc89/small/dentspa-logo-blue-png.png https://www.healthylivingmaldives.com/article/905432311-transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer Healthy Living Maldives en PressRelease 2026-04-13T06:00:00+00:00 Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer https://ml-eu.globenewswire.com/media/a1e966ec-4255-431c-b28a-c40c9e1f8733/small/transgene-logo-rvb2026-png.png https://www.healthylivingmaldives.com/article/905432314-transgene-annonce-la-fin-de-la-randomisation-des-patients-de-la-partie-phase-2-de-l-essai-clinique-valuant-tg4050-dans-le-traitement-adjuvant-des Healthy Living Maldives en PressRelease 2026-04-13T06:00:00+00:00 Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou https://ml-eu.globenewswire.com/media/2a0cee23-0b14-48ff-8db2-e5e966dd7bb5/small/transgene-logo-rvb2026-png.png https://www.healthylivingmaldives.com/article/905432318-synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study-supporting-emactuzumab-as-a-differentiated-next-generation Healthy Living Maldives en PressRelease 2026-04-13T06:00:00+00:00 SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) https://ml.globenewswire.com/media/35d87dbe-62e3-4299-9eba-3ccdbea5d85e/small/synox-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous Healthy Living Maldives en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez Healthy Living Maldives en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905424246-data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with-ethionamide-alpe Healthy Living Maldives en PressRelease 2026-04-13T05:00:00+00:00 Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://www.healthylivingmaldives.com/article/905424249-dupixent-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu Healthy Living Maldives en PressRelease 2026-04-13T05:00:00+00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthylivingmaldives.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia Healthy Living Maldives en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.healthylivingmaldives.com/article/905363129-scrap-the-ban-keep-the-controls-caphra-s-message-to-bangladesh Healthy Living Maldives en PressRelease 2026-04-12T20:56:25+00:00 Scrap the Ban, Keep the Controls: CAPHRA's Message to Bangladesh https://ml.globenewswire.com/media/6dc95f2d-65fb-409f-aed4-9ebe55554004/small/picture1-png.png https://www.healthylivingmaldives.com/article/905140755-upcoming-national-women-s-health-week-promoting-scalp-care-and-breathable-wig-solutions Healthy Living Maldives en PressRelease 2026-04-11T14:00:00+00:00 Upcoming National Women’s Health Week: Promoting Scalp Care and Breathable Wig Solutions https://ml.globenewswire.com/media/OTI3YTJhY2UtNjYzMS00YWRhLWE4MTgtYTNmYTI2NWY1Yjg5LTEzMTk4MDUtMjAyNi0wNC0xMS1lbg==/tiny/Klaiyi-Hair.png